Get started
Author

Anastasia Nika

ORCID: 0000-0003-1031-1753
Observed ORCID: 0000-0003-1031-1753
OpenAlex ID: A5049803569
Abstract 2162: Inhibition of GPR65 counteracts low pH induced immunosuppressive polarization of macrophages: In vitro and in vivo characterization of potent, selective and orally bioavailable small molecule GPR65 antagonists
2022 · Barbara Cipriani, David Miller, et al. · Cancer Research · 8
An immunomodulating peptide with potential to suppress tumour growth and autoimmunity
2023 · Michael Agrez, Christopher Chandler, et al. · Scientific Reports · 5
PDF
An immunomodulating peptide to counteract solar radiation-induced immunosuppression and DNA damage
2023 · Michael Agrez, Mark Stephen Rybchyn, et al. · Scientific Reports · 5
PDF
Abstract 1631: GPR65 is a critical mediator of low pH induced immunosuppressive signalling in tumor associated macrophages: Human target validation of GPR65 as a novel innate immune checkpoint and discovery of potent, selective GPR65 antagonists
2021 · Barbara Cipriani, Alan Naylor, et al. · Cancer Research · 5
Synthesis and characterization of low molar mass end-functionalized homo- and copolymers with ureidopyrimidone, UPy groups
2020 · Spyridoula-Lida Bitsi, Maria Stogiou, et al. · Colloid & Polymer Science · 5
An Immunomodulating Peptide with Potential to Promote Anticancer Immunity Without Compromising Immune Tolerance
2025 · Michael Agrez, Christopher Chandler, et al. · Biomedicines · 3
PDF
Abstract 668: The translational biology of small molecule GPR65 inhibitors: shared effects between mouse models and human primary tumors highlight the unique transformative potential of targeting a genetically validated innate immune checkpoint
2023 · Barbara Cipriani, Alastair Corbin, et al. · Cancer Research · 3
Abstract 3877: MPL-5821, a macrophage targeted ESMTM p38 MAPK inhibitor, inhibits the production of TLR agonist induced IL-10 whilst sparing T-cell functionality
2018 · David Moffat, Martin Perry, et al. · Cancer Research · 3
1324 Inhibition of acid sensing by GPR65 normalises gene expression in macrophages, increases immune cell infiltration in tumors, and restrains subcutaneous MC38 growth in mice
2022 · Alastair Corbin, Stuart Hughes, et al. · Journal for ImmunoTherapy of Cancer · 2
PDF
497 PTT-4256 is a first-in-class small molecule inhibitor of GPR65 that counteracts the low pH-dependent immunosuppressive effects on immune cells and displays pronounced anti-tumor activity in mice
2023 · Alastair Corbin, Barbara Cipriani, et al. · Journal for ImmunoTherapy of Cancer · 1
PDF
A novel immunomodulating peptide with potential to complement oligodeoxynucleotide-mediated adjuvanticity in vaccination strategies
2024 · Michael Agrez, Christopher Chandler, et al. · Scientific Reports
PDF
Works count: 11
Citation count: 40
H-index: 5
I10-index:
Year
Topic
Type